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Abstract 
Objectives: First, to estimate the added value of a clinical decision support system (CDSS) in the performance of 
medication reviews in hospitalised elderly. Second, to identify the limitations of the current CDSS by analysing gener‑
ated drug‑related problems (DRPs).
Methods: Medication reviews were performed in patients admitted to the geriatric ward of the Zuyderland medical 
centre. Additionally, electronically available patient information was introduced into a CDSS. The DRP notifications 
generated by the CDSS were compared with those found in the medication review. The DRP notifications were ana‑
lysed to learn how to improve the CDSS.
Results: A total of 223 DRP strategies were identified during the medication reviews. The CDSS generated 70 clini‑
cally relevant DRP notifications. Of these DRP notifications, 63 % (44) were also found during the medication reviews. 
The CDSS generated 10 % (26) new DRP notifications and conveyed 28 % (70) of all 249 clinically relevant DRPs that 
were found. Classification of the CDSS generated DRP notifications related to ‘medication error type’ revealed that 
‘contraindications/interactions/side effects’ and ‘indication without medication’ were the main categories not identi‑
fied during the manual medication review. The error types ‘medication without indication’, ‘double medication’, and 
‘wrong medication’ were mostly not identified by the CDSS.
Conclusions: The CDSS used in this study is not yet sufficiently advanced to replace the manual medication review, 
though it does add value to the manual medication review. The strengths and weaknesses of the current CDSS can be 
determined according to the medication error types.
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Background
Frailty in the aging patient is a state of vulnerability in 
which health status can suddenly decrease as a result of 
relatively small health events (Clegg et  al. 2013). Ulti-
mately frailty may lead to considerable disability. Frail 
elderly often have multiple chronic conditions which are 
associated with the use of many drugs. Polypharmacy 
is often defined as the use of more than five drugs per 
patient. This is an arbitrarily chosen cut-off point and 
varies between studies. Alternatively, polypharmacy can 
be defined as the use of a higher number of drugs than 
clinically indicated (Maher et al. 2014; Hajjar et al. 2007). 
Both polypharmacy and frailty are independently associ-
ated with morbidity intensity suggesting a direct effect 
of polypharmacy on a patient’s frailty status. The influ-
ence of polypharmacy on frailty might be explained by 
decreased compliance, more adverse drug reactions 
(ADR), and drug interactions. Excessive polypharmacy, 
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which is the use of more than ten drugs, is an independ-
ent risk factor for mortality (Herr et al. 2015).
A drug-related problem (DRP) is “an event or a circum-
stance involving drug therapy that actually or potentially 
interferes with health care outcome” (Silva et  al. 2015). 
DRPs are associated with (frail) elderly as a consequence 
of polypharmacy, complex dosing regimens as well as 
alterations in pharmacokinetics and pharmacodynamics. 
DRPs are also associated with cognitive and functional 
status (Silva et al. 2015).
Leendertse et al. showed that polypharmacy is an inde-
pendent risk factor for hospitalisation. Of the unplanned 
hospital admissions 5.6  % were medication-related. Of 
these almost half were probably preventable (Leendertse 
et al. 2008). Paradoxically, polypharmacy has been shown 
to increase during hospitalisation of elderly (Nobili et al. 
2011).
Medication review
A medication review is defined as a structured evalu-
ation of a patient’s medication by a physician and a 
pharmacist, taking into account medical history and 
laboratory values. The medication review aims to reach 
agreement about drug therapy in order to optimise the 
impact of medication while minimising the number of 
medication-related problems. When the patient’s input 
into the medication review is included with all available 
patient’s information, the review is defined as a clini-
cal medication review. Without the patient’s input, the 
review is defined as a treatment review. This is often the 
case in hospitalised patients (Blenkinsopp et al. 2012; van 
Dijk et al. 2009). It has been suggested that there should 
be an intermediate definition for hospitalised patients, 
since patients are followed up daily by nursing staff and 
physicians, while recognising that dementing or very ill 
patients cannot give comments on their medication (van 
Dijk et  al. 2009). In a systematic review by Christensen 
et  al. no conclusive benefits on future hospitalisations 
or mortality in hospitalised patients are shown when 
performing medication reviews. However, performing 
medication reviews has shown to reduce the number 
of emergency department contacts (Christensen and 
Lundh 2013). Furthermore, it has been shown that reg-
ular revision of medication reduces DRPs and improves 
medication appropriateness (Alldred et  al. 2013). The 
inconsistency of proven benefits of medication reviews 
might be caused by implementation problems. These 
problems involve the time efficiency of performing medi-
cation reviews as well as the structure and information 
used in a medication review. The output consistency of 
the health care professionals performing the medication 
reviews can also be a factor (de Wit et al. 2014b; Hurk-
ens et  al. 2013; Mestres Gonzalvo et  al. 2015). These 
problems might be (partially) resolved by automation of 
the medication review (de Wit et al. 2013).
Clinical decision support systems (CDSS)
The Dutch Healthcare Inspectorate (IGZ) requires physi-
cians to prescribe exclusively using computerised physi-
cian order entry (CPOE) systems with an integrated drug 
safety alert system.
In the Netherlands, a nationwide drug database is 
maintained by the Royal Dutch Association for the 
Advancement of Pharmacy (KNMP) that generates 
drug safety alerts to ensure medication surveillance 
which include dosage appropriateness, double medica-
tion, drug–drug interactions, and drug contraindica-
tions (Richtlijn elektronisch voorschrijven 2013). The 
pharmacist responsible for the CPOE can regulate 
the drug safety alerts to a degree (Eppenga et  al. 2012). 
These alerts result from relatively uncomplicated algo-
rithms that form a basic clinical decision support sys-
tem (CDSS) (Kuperman et al. 2007). The use of a CDSS 
with advanced algorithms that combine medication and 
laboratory values is becoming common practice in the 
Netherlands, and the use of advanced algorithms that 
incorporate guidelines and drug–disease interactions 
that initiate treatment to prevent adverse drug events is 
up-coming (Rommers et al. 2011; O’Sullivan et al. 2014; 
Meulendijk et al. 2015). Unlike the basic algorithms that 
are routinely integrated into CPOEs, the advanced algo-
rithms are mostly not integrated into a CPOE. Integra-
tion of a CDSS into a CPOE results in the presentation 
of alerts when a physician is prescribing medication. In 
this way the physician can adjust the prescription during 
the prescription process if necessary, instead of adjust-
ing the prescription afterwards, such as when it is initi-
ated by an alert from a stand-alone CDSS (de Wit et al. 
2015; Eppenga et al. 2012; Tawadrous et al. 2011). Patient 
outcome benefits of using advanced CDSSs remain lim-
ited, but several studies do report positive results related 
to prevention of adverse drug events (Rommers et  al. 
2011; Tawadrous et  al. 2011; Bright et  al. 2012; Jaspers 
et al. 2011). Bright et al. (2012) have shown in a system-
atic review that CDSSs do influence ‘health care process 
measures’ by improving the initiated treatment or pre-
ventive care in terms of: pharmacotherapy, laboratory 
test ordering, and chronic disease management.
In a recent study, the use of an advanced CDSS to sup-
port medication reviews in older hospitalised patients 
has shown to improve the appropriateness and accuracy 
of medication regimens (O’Sullivan et al. 2014).
The department of clinical pharmacy and toxicol-
ogy of the Zuyderland medical centre has developed an 
advanced CDSS based on our experience with a simpler 
access based CDSS (de Wit et  al. 2015). The currently 
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developed advanced CDSS consists of algorithms that 
alert for the inappropriate combination of medication 
and laboratory values, for lack of guideline implemen-
tation, and gives suggestions to prevent adverse drug 
events as a result of drug–disease interactions. The devel-
opment phases of the CDSS have been described in more 
detail previously (de Wit et al. 2013). The content devel-
opment team consisted of several hospital pharmacists 
and internists, a neuropsychiatrist, and a nursing home 
physician. In the Netherlands, nursing home medicine 
is an officially recognised medical discipline for physi-
cians attending nursing homes (Schols et  al. 2004). The 
content was based on national guidelines, protocols and 
relevant studies. The CDSS consists of 469 clinical rules 
aiming to have a high sensitivity and specificity. This 
standalone CDSS has been developed to support medica-
tion reviews in synergy with the already integrated CPOE 
drug safety alerts that consider dosage appropriateness, 
double medication, drug–drug interactions, and drug 
contraindications.
The aim of this study was to estimate the value of this 
CDSS regarding the performance of medication reviews 
in hospitalised elderly by comparing DRPs taken from a 
multidisciplinary treatment review to the DRP notifica-
tions prompted by the CDSS. Furthermore, we aimed to 
identify the limitations of the current CDSS by analysing 
the CDSS generated DRP notifications.
Methods
From November 2012 to December 2013 medication 
reviews were performed in clinical patients admitted 
to the geriatric ward of the Zuyderland medical cen-
tre, located in Sittard-Geleen. The medication reviews 
were performed during the weekly ‘gerontopharmacol-
ogy meeting’. During every gerontopharmacology meet-
ing one patient was discussed for 0.5–1  h. The patients 
were selected by the geriatrician and communicated 
to all the participants before the meeting. At least one 
geriatrician (leading practitioner and chairman of the 
meeting), one resident and one hospital pharmacist (in 
training) attended the meeting. In most cases, more cli-
nicians attended, including geriatricians, residents, nurse 
practitioners and medical students. The meeting was 
also intended to provide educational value. The leading 
practitioner and chairman of the meeting was either a 
geriatrician or an internist, with a subspecialty in old age 
medicine. Both are geriatric experts, and have expertise 
in medical education. The attending hospital pharmacist 
had extensive experience in performing structured medi-
cation reviews, as necessary for this study. Apart from 
these experts, up to 5 postgraduate physician residents 
and 5 medical students attended the meeting.
The structure of the review was based on the method 
used in the PHARM-study and was followed during the 
medication reviews (Leendertse et  al. 2011). This struc-
ture was: (1) Matching the prescribed medication with 
the known indications, (2) Matching indications with 
prescribed medications, (3) Relating the laboratory val-
ues to the prescribed medication, (4) A general discus-
sion whether there were other suggestions based on the 
patients’ or nurses input. Although the pharmacist did not 
perform patients’ interviews, the geriatrician and residents 
had daily contact with the reviewed patients, and any rel-
evant information was then presented in the meeting. The 
indirect input of patients’ comments causes these medica-
tion reviews to supersede the requirements of a standard 
“treatment review”, but does not meet the requirements of 
a “clinical medication review”. For this study, we will con-
tinue to address them as medication reviews.
The hospital pharmacist prepared the medication 
review by documenting the DRP suggestions resulting 
from the manual check of medications, laboratory values, 
and other relevant clinical patient information. These 
suggestions were discussed during the medication review 
by the attendants. If they were accepted by the attend-
ants as a DRP, it was included as a strategy to improve 
the patient’s therapy. The accepted ‘DRP strategies’ were 
documented by the hospital pharmacist. A week after 
the medication review the hospital pharmacist docu-
mented which DRPs had indeed been executed. In this 
study, we will discuss the DRPs using the following terms: 
“DRP suggestions” (when DRPs were identified during 
the pharmacist’s preparation), “DRP remarks” (newly 
introduced DRPs during the medication review), “DRP 
strategies” (when DRPs were accepted as therapy strate-
gies for the patient during the medication review), “DRP 
notifications” (the DRPs found by the CDSS), and “DRPs 
executed” (the carried out therapy strategies based on the 
DRP strategies).
In addition, prior to the gerontopharmacology meet-
ing the hospital pharmacist extracted all electronic avail-
able patient information: laboratory values, medication, 
and documented indications and contraindications. The 
extracted electronic patient information was introduced 
into the CDSS in April 2015, therefore it was not pos-
sible that the medication reviews identified DRPs were 
influenced by the CDSS generated DRPs. The CDSS is 
designed to exclusively alert for relevant DRPs (DRP 
notifications). This is done by including ‘triggers’ that 
allow assessing whether the predefined DRPs are relevant 
or non-relevant. For example, there is an algorithm alert-
ing for the prescription of a gastrointestinal prophylaxis 
in a patient at risk. However, for some patients a proph-
ylaxis will already be prescribed and this notification is 
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therefore assessed as a non-relevant notification by the 
CDSS. The DRP notifications from the CDSS were inde-
pendently checked for relevancy and classified for type 
of medication error by hospital pharmacist HW and 
geriatrician KM. In case of disagreement, consensus was 
obtained by discussing on a case by case basis.
The local Medical Research & Ethics Committee 
(MREC) determined this study to be non-accessory for 
the Dutch Medical Research in Human Subjects Act 
(non-WMO).
Numerical variables were presented by mean (SD; 
range, i.e. minimum–maximum value) and categorical 
ones by number (%). The descriptive statistics were com-
puted using Microsoft Excel 2010.
Results
We held 33 documented gerontopharmacology meetings 
during which 33 medication reviews were performed, 
all on different patients. The mean age of the reviewed 
patients was 83  years (SD 8.0; range 69–97). Gen-
der was distributed almost equally with 55  % (n  =  18) 
of the patients being male. The mean amount of pre-
scribed drugs per patient was 15.2 (SD 4.0; range 8–27 
medicines).
Drug‑related problems
The pharmacist who prepared the gerontopharmacology 
meeting had a total of 221 DRP suggestions based on the 
33 medication reviews. Of these 221 DRP suggestions, 
166 DRP suggestions were accepted as DRP strategies, 
while 55 DRP suggestions were rejected and an addi-
tional 57 DRP remarks were introduced during the meet-
ing and accepted as DRP strategies. Thus, a total of 223 
DRP strategies were accepted with a mean of 7.0 (SD 2.2; 
range 2–11) per patient (see Fig. 1).
The CDSS generated 574 DRP notifications. Of these 
notifications the CDSS determined 516 to be non-rele-
vant notifications. The remaining 58 DRP notifications 
were determined as relevant DRP notifications by the 
CDSS. These 58 CDSS DRP notifications were checked 
by HW and KM, 51 of which were considered clini-
cally relevant for the patient. In addition, HW and KM 
confirmed 19 notifications that were assessed as non-
relevant by the CDSS to be clinically relevant DRP notifi-
cations. In total 70 DRP notifications issued by the CDSS 
were relevant (see Fig. 1).
Of the confirmed relevant CDSS DRP notifications, 
63 % (44) DRP notifications were also noted and accepted 
as DRP strategies in the medication reviews. Twenty-six 
DRP notifications from the CDSS had not been identified 
during the medication review but were assessed as clini-
cally relevant by HW and KM. Table 1 shows the CDSS 
DRP notifications that went unnoticed in the medication 
reviews.
These 44 DRP notifications covered 20  % of the DRP 
strategies identified in the medication review. The CDSS 
generated an additional 26 newly confirmed DRP strate-
gies (see Fig. 1). The 223 DRP strategies from the medica-
tion reviews combined with the additional 26 confirmed 
relevant DRP notifications from the CDSS, add up to a 
total of 249 DRP strategies. The CDSS generated 28.1 % 
(70) of all 249 DRPs strategies of which 10  % (26) were 
new notifications.
The 223 DRP strategies determined in the medication 
reviews were followed up for implementation a week 
after the medication review. Fifty-five percent (121) of 
these DRP strategies were executed a week after the med-
ication review, which is a mean 3.8 (SD 2.3; range 0–9) 
DRPs executed per patient.
Classification of drug‑related problems
All DRPs were categorised according to a seven-fold 
‘medication error type’ classification (see Table  2). 
Table 2 shows that two medication error types (a) ‘indi-
cation without medication’ and (b) ‘medication with-
out indication’ made up more than half of the existing 
medication errors. The 26 relevant DRP notifications not 
recognised during the medication reviews were mainly 
medication errors type (c) ‘contraindications/interac-
tions/side effects’ and error type (a) ‘indication without 
medication’. The error types (b) ‘medication without indi-
cation’, (e) ‘double medication’, and (f ) ‘wrong medication’ 
were least likely to be identified by the CDSS.
CDSS efficiency
The efficiency of the CDSS was determined by calculat-
ing the sensitivity and specificity of the CDSS using the 
confirmed correctness of CDSS notifications. Fifty-one of 
the 58 DRP notifications were found true positive, giving 
a sensitivity of 72.9 %. Of the 516 DRPs assessed as non-
relevant notifications by the CDSS, 19 notifications were 
confirmed relevant by KH and HW giving 497 DRP true 
negative notifications resulting in a specificity of 98.6 %. 
In Table 3 the sensitivity and specificity are shown.
The confirmed clinically relevant CDSS notifica-
tions were analysed to determine the reasons why they 
were incorrectly assessed as relevant or irrelevant by 
the CDSS. In Table  4, the CDSS notifications assessed 
as non-relevant but confirmed as relevant are shown. 
In Table  5, the CDSS notifications assessed as relevant 
but confirmed as non-relevant are shown. The actions 
needed to improve the sensitivity and specificity of these 
algorithms varies considerably and are also shown in 
Tables 4 and 5.
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Discussion
This study shows that performing medication reviews 
in a hospitalised geriatric patient group can be of value 
when considering the mean of 7.0 (SD 2.2) DRP strate-
gies identified during the gerontopharmacology meet-
ings. The acceptance rate of the pharmacists suggestions 
was 74.4 % (166 out of 221 DRP suggestions) which cor-
responds with other described acceptance rates of DRP 
suggestions ranging from 39.0 to 91.6  % in long-term 
care patients and 65  % in hospitalised patients (Verrue 
et al. 2009; Mestres et al. 2015; van Dijk et al. 2009). In 
our study, we also investigated to which extend the DRP 
strategies were executed by the physician 1  week after 
the medication reviews. This resulted in 54.3  % (122) 
executed DRPs after 1 week. Another study reports that 
65 % of the DRP strategies were executed (van Dijk et al. 
2009). It should be mentioned that the patient group 
studied is easily susceptible to clinical changes, which 
might explain why physicians decided not to execute cer-
tain DRP strategies.
CDSS supports medication review
Despite the absence of conclusive benefits for morbidity 
and mortality, medication reviews feature prominently in 
pharmacists’ and physicians’ daily work (Hurkens et  al. 
2013; de Wit et al. 2014b; Wallerstedt et al. 2014; Chris-
tensen and Lundh 2013). Many other studies have shown 
improvement of medication safety in elderly with the 
support of a CDSS (Marasinghe 2015; Ranji et al. 2014). 
Whether a CDSS can support the manual medication 
review can be shown by comparing the confirmed DRP 
notifications with the DRP strategies of the medication 
reviews. This study shows that 20  % of the DRP strate-
gies were also identified by the CDSS. Furthermore, the 
CDSS identified 26 DRPs that were overlooked in the 
manual medication review showing that the CDSS adds 
value to performing the medication review manually. 
Meulendijk et al. (2015) also suggested that a CDSS may 
improve medication review effectiveness. However, the 
results also show the CDSS can be improved in efficiency 
and content.
Total of 249 relevant DRP’s
26 new relevant 
‘DRP notifications’121 DRP’s executed 
after a week
55 pharmacists’ ‘DRP 
suggestions’ not relevant
Medication review
Clinical Decision Support System
574 notifications
Pharmacists’ preparation
57 additional ‘DRP 
remarks’
166 pharmacist’s DRP suggestions
221 pharmacist’s ‘DRP suggestions’
223 ‘DRP strategies’ 70 ‘DRP notifcations’
44 Identical DRP’s
Evaluation of notifications   
58 DRP notifications
7 non-relevant ‘DRP 
notifications’ by KM & HW
19 wrongly CDSS assessed 
DRP notifications
516 assessed as non-
relevant by CDSS
51 DRP notifications
Fig. 1 Flowchart of DRPs from 33 medication reviews
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CDSSs strengths and weaknesses
The classification of types of medication errors shows 
that the notifications prompted by the CDSS, which 
went unrecognised during the medication reviews are 
strongly represented by the medication error types (c) 
‘contraindications/interactions/side effects’ and error 
type (a) ‘indication without medication’. The importance 
in recognising these medication error types has also been 
shown by Leendertse et al. in the evaluation of the poten-
tial causes of the preventable medication-related hos-
pital admissions. Their evaluation showed a variety of a 
number of potential causes like gastrointestinal problems 
such as bleeding and constipation and cardiovascular 
problems such as heart failure (Leendertse et  al. 2008). 
These cases also involved the medication error types (a) 
‘indication without medication’, and (c) ‘contraindica-
tions/interactions/side effects’, mostly missed in the med-
ication review but recognised by the CDSS.
The medication error types (b) ‘medication with-
out indication’, (e) ‘double medication’, and (f ) ‘wrong 
medication’ were frequently not identified by our CDSS. 
Depending on the medication error type, it can be rea-
soned why the CDSS did not find these types of errors. 
The medication error type (b) requires the input of the 
‘indication’. In the included medication reviews only 
three indications for all patients where documented 
in the CPOE and therefore available for the CDSS. It 
has already been suggested that multi-morbidity from 
electronic health records is poorly adopted by currents 
CDSSs (Fraccaro et al. 2015). The reason why the medi-
cation error types (e) ‘double medication’ and (f ) ‘wrong 
medication’ were not found by the CDSS is because these 
DRPs are not included in the algorithms. These DRPs are 
routinely screened by the physician and pharmacist in the 
CPOE integrated G-standard. Our CDSS has been devel-
oped to have new notifications in addition to the CPOE 
notifications. The appearance of the many medication 
Table 1 DRP notifications not identified in the medication 
review
Potassium level—drugs inducing hypokalemia
Use of aspirin, dipyridamol, clopidogrel, prasugrel without a statin
Calcium channel blockers with chronic constipation
Atypical antipsychotics combined with oral blood glucose lowering 
drugs or insulin
Atypical antipsychotics combined with Alzheimer medication
Nitrate without aspirin or clopidogrel, prasugrel, ticagrelor
Metformin with unknown vitamin B12 level
Renal failure with amoxicillin (oral)
Atypical antipsychotics combined with antihypertensive medication
Nitrate without a beta blocker
Nortriptyline usage in elderly patients
Tricyclic antidepressants with constipation
Paracetamol in elderly patients in combination with risk factors
Gastric protection without prophylaxis
Gastric protection, prophylaxis dosage not high enough
Classical antipsychotics with anticholinergic effects—start alpha blockers 
may be related to this effect
Tricyclic antidepressants with cardiac conductive abnormalities
Use of rheumatoid arthritis drugs without a statin
Bisphosphonates, calcium and vitamin D supplementation: suggest 
prescribing calcium
Renal failure with metoclopramide
Table 2 Classification of medication error types
The columns shows type of medication errors identified during the medication review and by our CDSS independently of the medication review. The last column 
shows the percentage of medication error types our CDSS did not identify

















a Indication without 
medication
94 (30.5 %) 76 (30.5 %) 29 (41 %) 68 (30.5 %) 8 (31 %) 47 (69.1 %)
b Medication with‑
out indication




32 (10.4 %) 25 (10.0 %) 20 (29 %) 11 (4.9 %) 14 (54 %) 5 (45.5 %)
d Dosage problems 42 (13.6 %) 35 (14.1 %) 14 (20 %) 31 (13.9 %) 4 (15 %) 21 (67.7 %)
e Double medication 10 (3.2 %) 7 (2.8 %) 0 7 (3.1 %) 0 7 (100 %)
f Wrong medication 26 (8.4 %) 22 (8.8 %) 1 (1 %) 22 (9.9 %) 0 21 (95.5 %)
g Therapeutic drug 
monitoring
26 (8.4 %) 18 (7.2 %) 4 (6 %) 18 (8.1 %) 0 14 (77.8 %)
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error types (e) ‘double medication’ and (f ) ‘wrong medi-
cation’, suggests there is a high degree of alert fatigue with 
regard to CPOE alerts. Alert fatigue occurs when there 
are a high number of non-clinically relevant alerts, which 
results in the overlooking of both relevant and not-rele-
vant alerts (van der Sijs et al. 2006). The CPOE integrated 
G-standard has been reported to generate 5.8 % relevant 
drug safety alerts (Eppenga et  al. 2012). The efficiency 
of our CDSS is much higher with a sensitivity of 72.9 % 
and a specificity of 98.6 %. The analysis of why the CDSS 
assessed DRP notifications as non-relevant or relevant, 
while later evaluated as relevant and non-relevant respec-
tively, can be used to increase the efficiency of the CDSS.
Limitations of the study
We attempted to estimate the added value of the devel-
oped CDSS and the effectiveness of the manual medi-
cation review. Our study was limited, however, to the 
performed medication reviews, the CDSS-generated 
DRP notifications and the DRPs executed within a week 
after the medication review. An analysis of why DRP 
strategies were not executed would perhaps have pro-
vided interesting insights into the execution part of the 
medication review process. Furthermore, all DRPs were 
classified according to the type of medication error 
observed. A few DRPs, however, involved consultations 
with other physicians concerning the use of certain drugs 








51 (A) 7 (B) 58 (A + B)
Non‑relevant DRP 
notifications
19 (C) 497 (D) 516 (C + D)
70 (A + C) 504 (B + D) N = 574
Table 4 CDSS notifications assessed as non-relevant but confirmed as relevant
DRP notifications DRP strategy in handmade  
medication review
Reason assessed as non‑relevant notification and  
improvement suggestion
Potassium levels—drugs inducing 
hyperkalemia
Stop potassium supplement with potas‑
sium level of 3.9
Cut‑off point for potassium (>5.5 mmol/l) was not reached. Cut‑
off point needs to be refined
Benzodiazepines and fall risk Stop or dose benzodiazepine ‘as needed’
Phase out benzodiazepine
Benzodiazepine usage should be stopped or reassessed when 
chronic
A predictive risk algorithm for falling might be developed
Paracetamol in elderly patients in combi‑
nation with risk factors
Stop paracetamol because of medica‑
tion induced headaches
Include code of International Statistical Classification of Diseases 
into algorithm
Nortriptyline in elderly: the maximum 
daily dose in elderly is 50 mg. If nor‑
triptyline is dosed higher, an ECG and 
monitoring of nortriptyline levels is 
recommended
No strategy Two separate prescriptions of nortriptyline: 10 mg and 50 mg. The 
two prescriptions should be combined by the CDSS to show the 
total dosage
Paracetamol in elderly in combination 
with risk factors
Chronic use of paracetamol should be 
reduced to a maximum of 3 g daily
Chronic paracetamol usage in higher dosages should be avoided. 
Additional risk factors should be included in the algorithm 
alongside the dosage
Renal Failure and Amoxicillin/Clavulanic 
acid (oral)
Renal function 32 ml/min and oral 
dosage amoxicillin/clavulanic acid 
increased
Too low dosages when renal function improves should be 
included in the algorithm
Alendronic acid usage longer than 
5 years
Consider whether continuation after 
5 years of use is necessary
The original prescription starting date was not taken into account 
when patient was admitted to hospital
Citalopram in elderly Prescribed dosage 30 mg, maximum 
dosage in elderly 20 mg
Two separate prescriptions citalopram; 10 and 20 mg. The two 
prescriptions should be combined by the CDSS in order to the 
total dosage
Anticoagulation therapy and INR Increase dosage since INR is too low The upper limit cut‑off point for >5.5 INR was not reached. The 
algorithm focusses on toxicity, while for medication reviews 
a lower limit should also be included to monitor therapeutic 
efficacy
Potassium levels—drugs inducing 
hyperkalemia
Elevated potassium level of 4.6 with 
Losartan (which contains potassium). 
Converted to another ATII‑antagonist
Cut‑off point is set to trigger when potassium > 5.5 mmol/l. The 
specific prescription of losartan is not included in the algorithm 
of drugs containing potassium
Opioids without laxative agents. Up to 
70 % of the patients using opioids 
experience opioid‑induced constipa‑
tion
Restart laxative agents when diarrhea 
has stopped
Prescription of laxative agents is temporarily stopped, but remains 
in the medication extraction.
Temporarily stopped drugs should not be included in extraction. 
An indicator for bowel movement (stool) might be introduced
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or involved reminders to evaluate the necessity of certain 
drugs. We classified these DRPs as relevant, since there 
was considerable doubt related to the chosen therapy. 
This might be interpreted differently in other studies.
Further research
Using automation to make medication reviews more effi-
cient is considered highly necessary according to a recent 
survey (de Wit et al. 2014b). There remain several differ-
ences between CDSSs both content and efficiency of cur-
rent CDSS varies considerably. Some CDSSs still rely on 
the manual input of a single patient’s details such as med-
ical history, medication and pathology. These CDSSs do 
support the medication review but are lacking in terms 
of time efficiency (de Wit et al. 2014a). The effectiveness 
of our CDSS to support medication reviews needs to be 
increased by 1) complementing the content with over-
looked DRP strategies from the medication review and 2) 
by optimising the DRP notifications that were incorrectly 
assessed by the CDSS.
Furthermore, the results of this study show that cer-
tain DRP notifications are correct when strictly following 
the applicable guideline, but are found to be irrelevant 
after discussion in the gerontopharmacology meeting. 
The development of algorithms allowing discriminating 
between patients to initiate ‘deprescribing’ or to specifi-
cally not initiate pharmacotherapy treatment will be a 
challenge. Deprescribing aims to reduce the use of drugs 
that are less beneficial, or even, detrimental taking into 
account the individual needs for therapy (Scott et  al. 
2015). The challenge of incorporating ‘deprescribing’ is 
shown by the lack of DRP notifications in medication 
error type (b) ‘medication without indication’. An exam-
ple of deprescribing and of not initiating pharmacother-
apy treatment is the prescription of statins. In our study, 
treatment with HMG CoA-reductase inhibitor (statins) 
was not initiated in ten patients because they were too 
frail and too old. The benefit of stopping statins or not 
initiating statins when life expectancy is limited should 
be considered in CDSSs (Holmes and Todd 2015). The 
development of algorithms approaching the level of 
expertise in the gerontopharmacology meeting will be a 
great challenge and improvement for the CDSS.
Conclusions
Performing medication reviews in a hospitalised geriat-
ric patient group can be of value seen the high number of 
accepted DRP strategies. More than half of the accepted 
DRP strategies were executed within 1 week. The distri-
bution of the relevant medication error types shows the 
strengths and weaknesses of the CDSS compared to the 
manual medication review in this study. Our developed 
CDSS is currently unable to replace the manual medica-
tion review. It can however be of additional value for the 
manual medication review. Further development of the 
current CDSS is needed to fully support manual medica-
tion reviews.
Abbreviations
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Table 5 CDSS notifications assessed as relevant but confirmed as non-relevant
DRP notifications Reason scored as non‑relevant Action needed to improve algorithm
Renal failure and Rosuvastatin: contra‑
indicated in renal failure
Renal function was 14 ml/min with a 
daily dose of 10 mg Rosuvastatin, 
which is acceptable when the dosage 
is slowly increased
Introduce Rosuvastatin dosage limits of renal dysfunction into the 
algorithm as well as start date of prescription
Metformin and unknown vitamin B12 
level
Vitamin B complex is prescribed. Vitamin 
B12 levels are regarded as irrelevant 
when supplemented
Prescription of vitamin B complex should be included in the 
algorithm. Furthermore, determined vitamin B12 levels should 
also be included in the algorithm
Tramadol and seizure: Tramadol should 
be used with caution in patients with 
a history of epilepsy and those on con‑
comitant seizure threshold‑lowering 
medication. Consider switching to 
other pain medication
Tramadol is contraindicated in epilepsy, 
associated drugs (nortriptyline) is 
prescribed for depression
Nortriptyline should be removed from the algorithm since this is 
not a standard therapy for epilepsy
Renal Failure and pregabalin: initial 
dose 75 mg per day, maximum dose 
300 mg per day
Renal function of 43 ml/min with a dos‑
age of 150 mg daily. Maximum dose 
was not exceeded
The algorithm should be adjusted to take into account the start‑
ing date of the prescription
Anticoagulation therapy and INR: aceno‑
coumarol
High INR, but already given anti‑dote 
vitamin K
Include the prescription of the anti‑dote vitamin K into the 
algorithm
Use of acetosal, dipyridamol, clopidogrel, 
prasugrel without a HMG CoA‑reduc‑
tase inhibitor therapy (statin)
Patients were considered too old of 
age for HMG CoA‑reductase inhibitor 
therapy
A frailty indicator might be considered for inclusion to deter‑
mine if a HMG CoA‑reductase inhibitor therapy should still be 
prescribed
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